Viktor Grunwald, Professor of Interdisciplinary Genitourinary (GU) Oncology at the University Hospital Essen, shared a post on X, about paper published in Clinical Genitourinary Cancer:
Authors: Grünwald Viktor, Bögemann Martin, Rafiyan Mohammad-Reza, Niegisch Günter, Schnabel Marco, Flörcken Anne, Maasberg Michael, Maintz Christoph, Zahn Mark-Oliver, Wortmann Anke, Hinkel Andreas, Casper Jochen, Darr C, Hilser Thomas, Schulze M, Sookthai Disorn, Ivanyi Philipp.
”Real-world cabozantinib after ICI:
- Similar efficacy (shorter OS) compared to METEOR.
- 62% had lower starting doses (<60mg).
- Similar outcome in low vs. 60 mg starting dose.
- Less toxicity with lower dose.
- Let’s re-think cabozantinib dosing.”
Source: Viktor Grunwald/X